Influenza Vaccination Strategy for Patients With Hematologic Malignancy

This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population

NCT Number	NCT07485855
Lead Sponsor	Asan Medical Center
Conditions	Hematologic Neoplasms, Influenza, Immunogenicity
Enrollment	60 participants
Start Date	2025-12-04
Primary Completion	2027-04-30 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-28